import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-oncology-market-report';

/**
 * Curated copy for the UAE oncology programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 450–520M 2026 → ~USD 736M 2030, ~11.5% CAGR).
 * Regulatory detail: MOHAP (federal), DHA (Dubai), DOH (Abu Dhabi), mandatory insurance, public guidance.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_ONCOLOGY_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Oncology Market Report 2026',
  metaTitle: 'UAE Oncology Market Report 2026 | BioNixus',
  metaDescription:
    'UAE oncology market ~USD 450–520M in 2026 (BioNixus analysis): MOHAP/DHA/DOH pathways, insurer prior authorization, Cleveland Clinic Abu Dhabi & premium private centres, immuno-oncology, precision oncology, medical tourism—Gulf intelligence.',
  heroLead:
    'This briefing reads UAE oncology through its real access architecture: three regulators, an insurance-funded private sector that carries most premium volume, flagship centres like Cleveland Clinic Abu Dhabi and Burjeel Medical City, and a medical-tourism inflow that lifts demand above resident epidemiology. It maps where insurer prior authorization—not registration—gates immuno-oncology and targeted therapy.',
  summaryPara1:
    'The UAE is the GCC’s premium oncology market and its specialist-care showcase, anchored by flagship centres including Cleveland Clinic Abu Dhabi, Burjeel Medical City, and American Hospital Dubai. BioNixus sizes the market at roughly USD 450–520 million in 2026, advancing toward about USD 736 million by 2030 at roughly 11.5% CAGR. Demand runs above what resident population alone would imply because medical tourism concentrates complex oncology at JCI-accredited private facilities at full international price points. Access is shaped less by registration than by the three-authority landscape (MOHAP federally, with DHA in Dubai and DOH in Abu Dhabi) and by mandatory-insurance prior-authorization rules that differ by emirate and payer. Innovative immuno-oncology, antibody-drug conjugates, and precision oncology compete in well-resourced private and government tertiary centres. Sizing reflects BioNixus market analysis, 2026, not unaudited panel extrapolation alone.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [UAE medical devices market report](/uae-medical-devices-market-report) for diagnostics and radiotherapy capital context, the [GCC oncology market report](/market-reports/gcc-oncology-market-report) for Gulf-wide benchmarking, the [Saudi Arabia oncology market report](/market-reports/saudi-arabia-oncology-market-report) for the larger neighbouring market, [oncology therapy research](/healthcare-market-research/therapy/oncology) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'MOHAP federal registration plus separate DHA (Dubai) and DOH (Abu Dhabi) facility and procurement requirements; mandatory-insurance prior authorization and step rules for immuno-oncology and targeted therapy varying by emirate and payer (Thiqa, Daman, and Dubai plans); medical-tourism volume lifting demand above resident epidemiology at premium JCI-accredited centres; precision-oncology and NGS access more mature than regional peers but concentrated in flagship hospitals; radiotherapy and infusion capacity expansion at Cleveland Clinic Abu Dhabi, Burjeel Medical City, and American Hospital Dubai shaping referral flows',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE oncology as an emirate-by-emirate, payer-by-payer system rather than a single national market. The same regimen can clear quickly under one Abu Dhabi insurer and stall under a Dubai plan’s step rules, while government tertiary centres and premium private hospitals run different formulary logic. We pair bilingual oncologist and pharmacist quantitative work with payer-medical-director and insurer depth, and we separate medical-tourism demand from resident demand so forecasts are not inflated by international patients who do not represent the local payer mix. Operational signals matter: NGS and companion-diagnostic turnaround (more mature here than in most of the region but still hospital-dependent), infusion and radiotherapy capacity at the flagship centres, and the prior-authorization documentation that insurers expect before approving high-cost agents. KOL maps follow real referral and tumour-board influence across the flagship institutions.',
  commercialOutlookParagraph:
    'The outlook to 2030 favours teams that win the insured premium channel without over-indexing on medical-tourism volume. Immuno-oncology, antibody-drug conjugates, and precision oncology will grow where flagship-centre capacity, diagnostics, and insurer policy align; biosimilars exert less tender pressure than in Saudi Arabia but still factor into private-payer cost control. Manufacturers should plan emirate-specific access dossiers, insurer medical-policy engagement, and patient-support operations that private payers increasingly expect documented. Because a relatively small number of institutions and insurers shape most premium volume, share assumptions should be stress-tested by emirate, payer archetype, and centre before regional revenue targets are locked—one flagship formulary or insurer policy shift can move a brand’s UAE trajectory materially.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—oncologist and oncology-pharmacist adoption surveys, payer and insurer medical-policy interviews, and centre-level access mapping where data is available. Epidemiology references use published UAE and regional ranges as planning inputs, separating resident from medical-tourism demand, and are not patient-level forecasts. Because emirate-level rules, insurer medical policies, and centre capacity change on short cycles, access and pricing statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or legal advice.',
  faqs: [
    {
      question: 'How large is the UAE oncology market in 2026?',
      answer:
        'BioNixus market analysis sizes UAE oncology at roughly USD 450–520 million in 2026, advancing toward about USD 736 million by 2030 at roughly 11.5% CAGR. It is the GCC’s premium oncology market, anchored by flagship centres such as Cleveland Clinic Abu Dhabi, Burjeel Medical City, and American Hospital Dubai. Demand runs above resident epidemiology because medical tourism concentrates complex oncology at JCI-accredited private facilities. Use the GCC oncology market report for Gulf-wide context and the Saudi Arabia oncology report for the larger neighbouring market.',
    },
    {
      question: 'How is oncology regulated across the UAE’s three authorities?',
      answer:
        'The UAE operates a three-authority model: MOHAP provides federal marketing authorisation, while DHA (Dubai) and DOH (Abu Dhabi) add facility licensing and procurement requirements for products used in their licensed hospitals. MOHAP registration is the entry point, but full access usually requires emirate-level listing plus insurer medical-policy approval. For oncology, the binding constraint is often mandatory-insurance prior authorization rather than registration. Teams should map the exact sequence for each target emirate: MOHAP approval, DHA or DOH facility access, then insurer prior-authorization and step-therapy rules.',
    },
    {
      question: 'How does reimbursement and prior authorization work for UAE oncology?',
      answer:
        'Most premium oncology volume sits in the insurance-funded private sector, so insurer medical policy is decisive. Prior-authorization and step rules for immuno-oncology, antibody-drug conjugates, and targeted therapy vary by emirate and payer—Abu Dhabi (including Thiqa and Daman-administered benefits) and Dubai plans apply different criteria and documentation. Government tertiary centres add their own formulary review. High-cost agents typically require diagnostic confirmation, line-of-therapy justification, and ongoing response documentation. BioNixus tracks these payer rules directly so commercial teams can build emirate-specific access dossiers rather than a single national submission.',
    },
    {
      question: 'What role does medical tourism play in UAE oncology demand?',
      answer:
        'The UAE is a regional hub for complex cancer care, and international patients concentrate at JCI-accredited flagship centres at full price points. This lifts oncology demand above what the resident population alone would generate, but it also distorts analytics: medical-tourism patients do not reflect the local payer mix or reimbursement pathway. BioNixus separates resident from medical-tourism demand in fieldwork so brand teams do not over-forecast addressable insured volume. The flagship centres—Cleveland Clinic Abu Dhabi, Burjeel Medical City, American Hospital Dubai—are also reference institutions whose protocols influence wider prescribing.',
    },
    {
      question: 'Which oncology classes are growing fastest in the UAE?',
      answer:
        'Immune checkpoint inhibitors anchor first-line use in well-resourced centres; antibody-drug conjugates are a fast-growing premium segment; and precision oncology is more mature here than in most regional peers, with comparatively strong NGS and companion-diagnostic availability at flagship hospitals. Biosimilars exert less tender pressure than in Saudi Arabia but feature in private-payer cost control. Cell therapy and advanced modalities are concentrated in a small number of centres. Growth is paced by insurer policy and centre capacity as much as by clinical evidence.',
    },
    {
      question: 'How does BioNixus help oncology teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE oncology programmes: oncologist and oncology-pharmacist adoption studies, insurer and payer medical-policy interviews, emirate-level access mapping across MOHAP, DHA, and DOH, prior-authorization and step-rule analysis, and KOL mapping across the flagship centres. We separate resident from medical-tourism demand and align deliverables to launch, access, or indication-expansion milestones, connecting UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, access-risk maps, objection libraries, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
